PrognosDx Health is combining its epigenetics technology with Accium BioSciences' accelerator mass spectronomy platform to develop predictive histone biomarker tests. The two companies hope to create tools that will help clinicians treat cancer. “We have identified specific studies that would help further define the developmental direction of various diagnostic tests and the potential benefits they may provide to specific patient populations," noted Accium president Ali Arjomand in a Genetic Engineering News report. Article